Alemtuzumab following natalizumab in highly active paediatric-onset multiple sclerosis

We evaluated the occurrence of infusion-associated reactions, severe adverse events and no evidence of disease activity 3 status of a therapeutic course consisting of natalizumab followed by alemtuzumab in paediatric-onset multiple sclerosis. Five paediatric-onset multiple sclerosis (age range 16–17...

Descripción completa

Detalles Bibliográficos
Autores principales: Margoni, Monica, Rinaldi, Francesca, Miante, Silvia, Franciotta, Silvia, Perini, Paola, Gallo, Paolo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2019
Materias:
Short Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6747861/
https://www.ncbi.nlm.nih.gov/pubmed/31555463
http://dx.doi.org/10.1177/2055217319875471

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6747861/
https://www.ncbi.nlm.nih.gov/pubmed/31555463
http://dx.doi.org/10.1177/2055217319875471

Ejemplares similares